Manu De Rycker

Academic, Principal Investigator/Senior Lecturer (Teaching and Research)

University of Dundee

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Manu De Rycker is a Principal Investigator and Senior Lecturer at the University of Dundee, UK. His research focuses on drug discovery and pharmacological studies related to neglected tropical diseases, particularly those caused by Leishmania and Trypanosoma species. Recent publications highlight his contributions to identifying potent inhibitors and understanding the structural aspects of these pathogens relevant for therapeutic development.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (10)

David Horn

University of Dundee

UNITED KINGDOM

View details

Amanda Fortes Francisco

Assistant Professor

London School of Hygiene & Tropical Medicine

UNITED KINGDOM

View details

University of Dundee

UNITED KINGDOM

View details

Susan Wyllie

University of Dundee

UNITED KINGDOM

View details

Ian Gilbert

University of Dundee

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Manu De Rycker

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Pharmacological and structural understanding of the Trypanosoma cruzi proteasome provides key insights for developing site-specific inhibitors

Identification of potent inhibitors of Leishmania donovani and Leishmania infantum chagasi, the causative agents of Old and New World visceral leishmaniasis

Structure-activity relationships of 1,5-dihydro-2H-benzo[b][1,4]diazepine-2,4(3H)-diones as inhibitors of Trypanosoma cruzi

Validation of Trypanosoma cruzi inactivation techniques for laboratory use

Identification of a potent and selective LAPTc inhibitor by RapidFire-Mass Spectrometry, with antichagasic activity

Structure Guided Design and Synthesis of a Pyridazinone Series of Trypanosoma cruzi Proteasome Inhibitors

Development of a 2,4-diaminothiazole series for the treatment of human African trypanosomiasis highlights the importance of static-cidal screening of analogues

Anti-trypanosomatid drug discovery

Short-course combination treatment for experimental chronic Chagas disease

Identification and development of a series of disubstituted piperazines for the treatment of Chagas disease

Live-imaging rate-of-kill compound profiling for Chagas disease drug discovery with a new automated high-content assay

Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis

Identification and optimisation of a series of 8-hydroxy naphthyridines with potent in vitro antileishmanial activity: Initial SAR and assessment of in vivo activity.

Discovery of an Allosteric Binding Site in Kinetoplastid Methionyl-tRNA Synthetase.

The Qi Site of Cytochrome b is a Promiscuous Drug Target in Trypanosoma cruzi and Leishmania donovani.

Identification of 6-amino-1H-pyrazolo[3,4-d]pyrimidines with in vivo efficacy against visceral leishmaniasis

Collaborators (10)

David Horn

Amanda Fortes Francisco

Kevin D. Read

Richard J. Wall

David Gray

Alan Fairlamb

Gary Tarver

Fabio Zuccotto

Susan Wyllie

Ian Gilbert

Make your next move.